First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Kymera Therapeutics, Inc.
Study ID
NCT07412288
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • KT-579 — DRUG
    Oral drug
  • Placebo — DRUG
    Oral drug

Study Details

This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.

Key Dates

Start date
Feb 23, 2026
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
96 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER

Arms

  • Active Comparator: KT-579
    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-579.
  • Placebo Comparator: Placebo
    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.

Primary Outcome Measure

Incidence of adverse events [ Time Frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
CelerionLincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion· Lincoln, NE

Related Studies